期刊
NANO RESEARCH
卷 15, 期 3, 页码 2300-2314出版社
TSINGHUA UNIV PRESS
DOI: 10.1007/s12274-021-3813-1
关键词
photothermal therapy; Prussian blue nanoparticles; anti-CD137; melanoma; nanoimmunotherapy
类别
资金
- George Washington University (GWU) Flow Cytometry Core Facility
- GWU Office of Animal Research
- GWU Research Pathology Core Lab
- National Cancer Institute of the National Institutes of Health [R41CA217294, R37CA226171]
This study introduces a novel nanoimmunotherapy combining PBNP-PTT with aCD137 mAb therapy for melanoma, showing promising effects on tumor rejection through activated dendritic cells and tumor-infiltrating CD8(+) T cells, generating CD4(+) and CD8(+) T cell memory for tumor rechallenge rejection without long-term toxicity.
Despite the promise of immunotherapy such as the immune checkpoint inhibitors (ICIs) anti-PD-1 and anti-CTLA-4 for advanced melanoma, only 26%-52% of patients respond, and many experience grade III/IV immune-related adverse events. Motivated by the need for an effective therapy for patients non-responsive to clinically approved ICIs, we have developed a novel nanoimmunotherapy that combines locally administered Prussian blue nanoparticle-based photothermal therapy (PBNP-PTT) with systemically administered agonistic anti-CD137 monoclonal antibody therapy (aCD137). PBNP-PTT was administered at various thermal doses to melanoma cells in vitro, and was combined with aCD137 in vivo to test treatment effects on melanoma tumor progression, animal survival, immunological protection against tumor rechallenge, and hepatotoxicity. When administered at a melanoma-specific thermal dose, PBNP-PTT elicits immunogenic cell death (ICD) in melanoma cells and upregulates markers associated with antigen presentation and immune cell co-stimulation in vitro. Consequently, PBNP-PTT eliminates primary melanoma tumors in vivo, yielding long-term tumor-free survival. However, the antitumor immune effects generated by PBNP-PTT cannot eliminate secondary tumors, despite significantly slowing their growth. The addition of aCD137 enables significant abscopal efficacy and improvement of survival, functioning through activated dendritic cells and tumor-infiltrating CD8(+) T cells, and generates CD4(+) and CD8(+) T cell memory that manifests in the rejection of tumor rechallenge, with no long-term hepatotoxicity. This study describes for the first time a novel and effective nanoimmunotherapy combination of PBNP-PTT with aCD137 mAb therapy for melanoma.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据